The effect of carnitine on liver functio
Phase 3
Recruiting
- Conditions
- Surgery for repair of congenital heart lesions.
- Registration Number
- IRCT20180724040575N2
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Age 6 to 60 months
Cardiac repair surgery under the pump
Conscious consent of parents
Exclusion Criteria
Off pump operation
Known allergy to L-carnitine
Severe liver failure (liver enzymes more than twice normal)
Emergency operation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does L-carnitine modulate to improve postoperative liver function in congenital heart defect repairs in IRCT20180724040575N2?
How does oral L-carnitine compare to standard-of-care interventions in preventing hepatic injury after pediatric heart surgery in IRCT20180724040575N2?
Which biomarkers predict response to L-carnitine supplementation in children with congenital heart lesions undergoing surgery in IRCT20180724040575N2?
What are the safety profiles and adverse event management strategies for L-carnitine in pediatric cardiac surgery patients in IRCT20180724040575N2?
Are there combination therapies involving L-carnitine and other metabolic enhancers for postoperative liver protection in congenital heart defect repairs in IRCT20180724040575N2?